Feb 24, 2026Menopause and Perimenopause: Supplement Evidence for Hot Flashes, Bone Loss, and Cognitive SymptomsThe menopausal transition accelerates bone loss, cognitive change, sleep disruption, and cardiovascular risk. Supplement evidence varies sharply: isoflavones have modest hot flash data; calcium and vitamin D are well-supported for bone; magnesium helps sleep. Black cohosh is used widely but evidence is mixed.
Feb 21, 2026Longevity Protocol for Women Over 50: Evidence-Based PrioritiesPerimenopause and post-menopause mark a major metabolic and hormonal inflection point. This protocol covers the highest-leverage interventions for women over 50, grounded in current evidence.
Feb 20, 2026Osteopenia and Fragility: Protein, Vitamin D3, and K2 in a Training-First PlanFor osteopenia and fragility risk, mechanical loading and fall prevention remain primary. Vitamin D3, K2, whey protein, and creatine may provide selective additive support.
Feb 18, 2026Dasatinib and Quercetin for Senolytic Therapy: Mayo Clinic Phase 2 Trial FindingsA Mayo Clinic Phase 2 trial tested dasatinib plus quercetin in 60 older women with low bone density, finding improved bone formation markers. Dasatinib is an FDA-approved cancer drug requiring physician supervision.
Feb 16, 2026Collagen Peptides: Joint Pain, Skin Aging, Bone Density, and Bioavailability EvidenceHydrolyzed collagen peptides are absorbed as dipeptides and tripeptides that accumulate in cartilage, skin, and bone tissue. RCTs show meaningful joint pain reduction in osteoarthritis and sports-related joint discomfort. Skin hydration and elasticity benefits are well-replicated. Evidence for bone density is emerging.
Jan 7, 2026Vitamin K2 and Arterial Calcification: MK-4 vs MK-7, Bone and Vascular HealthVitamin K2 activates Matrix Gla Protein, which inhibits arterial calcification, and osteocalcin for bone mineralization. MK-7 has superior half-life and bioavailability vs MK-4.